Early Phase 1 Type 1 Diabetes Trial, Recruiting NCT06338553 Sponsor: Vanderbilt University Medical Center Condition: Type 1 Diabetes
Back to Type 1 Diabetes

Early Phase 1 Type 1 Diabetes Trial, Recruiting

NCT06338553
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

This trial has two separate parts with different eligibility requirements:

Part 1 (Aims 1–3): For people with early-stage type 1 diabetes (Stage 2)

  • You are between 12 and 50 years old
  • Your body weight falls within a healthy range for your age (BMI 18–31 for adults, or between the 5th and 95th percentile for children/teens)
  • You have tested positive for 2 or more diabetes-related antibodies in your blood, AND your blood sugar results fall in a specific "at-risk" range — not yet diabetic, but higher than normal (confirm with trial site for exact test results)

Part 2 (Aim 4): For people recently diagnosed with early-stage type 1 diabetes (Stage 3)

  • You are between 12 and 50 years old
  • Your body weight falls within a healthy range for your age (BMI 18–31 for adults, or between the 5th and 95th percentile for children/teens)
  • Your blood sugar control reading (HbA1c) was between 6.5% and 8.0% at diagnosis, OR between 5.7% and 6.4% with a confirming blood sugar test done within the past 3 months
  • Your Stage 3 diabetes diagnosis was made within the last 8 weeks before your first study visit

Who may not be able to join:

For Part 1 (Aims 1–3):

  • You have high blood pressure above a certain level (confirm with trial site)
  • Your kidneys are not functioning well enough based on a blood test (confirm with trial site)
  • Your liver enzyme levels are significantly higher than normal based on blood tests (confirm with trial site)
  • Anyone in your family has been diagnosed with a specific type of thyroid cancer called medullary thyroid carcinoma
  • You have been diagnosed with pancreas inflammation (pancreatitis) or a stomach-emptying condition (gastroparesis) in the past 3 years
  • You are currently taking any diabetes medication, certain blood pressure medications (such as atenolol, metoprolol, or propranolol), antipsychotic medications, steroids, growth hormone, cholesterol-lowering medications, water pills (thiazide diuretics), niacin supplements, certain birth control pills with higher hormone doses, or any medication that suppresses the immune system
  • You have taken antioxidant vitamin supplements within 2 weeks before the study
  • You are currently pregnant
  • You are a woman who is in or past menopause
  • You are an active smoker

For Part 2 (Aim 4):

  • You have ever been admitted to hospital due to a serious diabetes-related complication called diabetic ketoacidosis (DKA)
  • Anyone in your family has been diagnosed with medullary thyroid carcinoma (a specific type of thyroid cancer)
  • You have been diagnosed with pancreas inflammation (pancreatitis) or a stomach-emptying condition (gastroparesis) in the past 3 years
  • You are currently taking any diabetes medication, certain blood pressure medications (such as atenolol, metoprolol, or propranolol), antipsychotic medications, steroids, growth hormone, cholesterol-lowering medications, water pills (thiazide diuretics), niacin supplements, certain birth control pills with higher hormone doses, or any medication that suppresses the immune system
  • You have taken antioxidant vitamin supplements within 2 weeks before the study
  • You are currently pregnant
  • You are a woman who is in or past menopause
  • You are an active smoker

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Phone: (615) 322- 7427

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Registry
ClinicalTrials.gov
Start date
12 June 2024
Est. completion
1 March 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Investigate the impact of GLP-1Ra on postprandial glycemia in a pilot study; Study the impact of GLP-1Ra on the disposition index (DI) in a pilot study; Determine the impact of GLP-1Ra on endothelial function in a pilot study; Determine how much GLP-1Ra monotherapy therapy changes the disposition index (DI) in a pilot study of early stage 3 T1DM.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov